Zejula Added to UK’s Cancer Drugs Fund for Recurrent, Platinum-sensitive Ovarian Cancer

Zejula Added to UK’s Cancer Drugs Fund for Recurrent, Platinum-sensitive Ovarian Cancer
Women in England and Wales with recurrent, platinum-sensitive ovarian cancer can now access Zejula (niraparib) through the Cancer Drugs Fund (CDF) after a recommendation by the U.K.’s National Institute for Health and Care Excellence (NICE). Zejula, developed by Tesaro, is a poly(ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance of ovarian cancer patients who are in a complete or

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *